Avalo Therapeutics (AVTX) Cash from Financing Activities (2014 - 2026)

Avalo Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (down 76.22% YoY) and the FY2025 annual result came in at $14.6 million, down 91.7% from the prior year.
• Cash from Financing Activities was $1.4 million for Q1 2026 at Avalo Therapeutics, up from $687000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $108.6 million in Q1 2024 and bottomed at -$14.8 million in Q2 2022.
• A 5-year average of $15.6 million and a median of $687000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 6770800.0% in 2024, while the deepest fall reached 178.93% in 2024.
• Avalo Therapeutics' Cash from Financing Activities stood at $82000.0 in 2022, then tumbled by 98.78% to $1000.0 in 2023, then soared by 6770800.0% to $67.7 million in 2024, then plunged by 98.99% to $687000.0 in 2025, then soared by 103.64% to $1.4 million in 2026.
• Business Quant data shows AVTX's Cash from Financing Activities at $1.4 million in Q1 2026, $687000.0 in Q4 2025, and $14.4 million in Q3 2025.